NPCE · NeuroPace Inc
$14.77
+0.09 (+0.61%)
At close · Jul 24
Market Cap
$504.93M
Shares
34.09M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joel Becker | CEO | $2,408,566 |
| Patrick F. Williams | CFO | $1,645,935 |
| Martha Morrell | Chief Medical Officer | $1,034,132 |
| Rebecca Kuhn | CFO | $846,308 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joel Becker | CEO | $3,024,894 |
| Martha Morrell | Chief Medical Officer | $1,169,551 |
| Rebecca Kuhn | CFO | $1,093,306 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Favet | CEO | $2,179,174 |
| Joel Becker | CEO | $1,511,674 |
| Martha Morrell | Chief Medical Officer | $1,108,676 |
| Rebecca Kuhn | CFO | $994,911 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Favet | CEO | $3,206,303 |
| Martha Morrell | Chief Medical Officer | $1,315,429 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Favet | CEO | $2,076,341 |
| Irina Ridley | General Counsel | $1,008,484 |
| Martha Morrell | Chief Medical Officer | $964,933 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Favet | CEO | $671,592 |
| Martha Morrell | Chief Medical Officer | $483,982 |